Latest news articles

Added 1 month ago Drug news

NEJM publishes MEDALIST study results for Reblozyl to treat anemia in myelodysplastic syndromes.- BMS + Acceleration Pharma

Bristol-Myers Squibb Company and Acceleron Pharma Inc. announced that the New England Journal of Medicine (NEJM) has published results from...

Added 2 months ago Drug news

Reblozyl studies evaluating treatment of anemia in myelofibrosis-associated anemia presented at American Society of Hematology (ASH) meeting .BMS + Acceleron Pharma

Bristol-Myers Squibb Company and Acceleron Pharma announced data evaluating the erythroid maturation agent (EMA) Reblozyl (luspatercept-aamt) in patients with anemia...

Added 2 months ago Drug news

ASCERTAIN phase III trial of ASTX 727 meets primary endpoint in myelodysplastic syndromes.- Astex Pharma

Astex Pharmaceuticals presented topline data from the ASCERTAIN phase III trial of the orally administered fixed dose combination of ASTX727...

Search all news articles for Neoplasms of unspecified nature or uncertain behaviour
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Guidelines

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...

Added 4 years ago

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Adult soft tissue and visceral sarcomas (excluding gastrointestinal stromal tumor, GIST) are rare tumors, with an estimated incidence averaging 4–5/100 000/year in Europe.

Added 5 years ago

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis...

Added 5 years ago

Search all guidelines for Neoplasms of unspecified nature or uncertain behaviour
 

Journal articles

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT)...

Added 9 months ago

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade...

Added 10 months ago

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

The aim of the present retrospective study is to build a comprehensive picture of all alternative REG strategies adopted in daily clinical practice for use in metastatic GIST patients.

Added 1 year ago

Search all journal articles for Neoplasms of unspecified nature or uncertain behaviour
 

Clinical trials

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to IPSS-R very low, low, or intermediate MDS...

Added 1 year ago

Search all clinical trials for Neoplasms of unspecified nature or uncertain behaviour